

available at [www.sciencedirect.com](http://www.sciencedirect.com)  
journal homepage: [www.europeanurology.com](http://www.europeanurology.com)



European Association of Urology



Platinum Priority – Brief Correspondence

Editorial by XXX on pp. x–y of this issue

## Early Recurrence Patterns Following Totally Intracorporeal Robot-assisted Radical Cystectomy: Results from the EAU Robotic Urology Section (ERUS) Scientific Working Group

Justin W. Collins<sup>a</sup>, Abolfazl Hosseini<sup>a</sup>, Christofer Adding<sup>a</sup>, Tommy Nyberg<sup>b</sup>, Anthony Koupparis<sup>c</sup>, Edward Rowe<sup>c</sup>, Matthew Perry<sup>d</sup>, Rami Issa<sup>d</sup>, Martin C. Schumacher<sup>e</sup>, Carl Wijburg<sup>f</sup>, Abdullah E. Canda<sup>g</sup>, Melvin D. Balbay<sup>h</sup>, Karel Decaestecker<sup>i</sup>, Christian Schwentner<sup>j</sup>, Arnulf Stenzl<sup>j</sup>, Sebastian Edeling<sup>k</sup>, Saša Pokupić<sup>k</sup>, Fredrik D'Hondt<sup>l</sup>, Alexander Mottrie<sup>l</sup>, Peter N. Wiklund<sup>a,\*</sup>

<sup>a</sup>Karolinska University Hospital, Stockholm, Sweden; <sup>b</sup>Karolinska Institute, Stockholm, Sweden; <sup>c</sup>Bristol Urological Institution, Bristol, UK; <sup>d</sup>St. Georges Hospital London, London, UK; <sup>e</sup>Hirslanden Klinik, Aarau, Switzerland; <sup>f</sup>Carl Wijburg, Rijnstate, Arnhem, The Netherlands; <sup>g</sup>Ankara Atatürk Hospital, Ankara, Turkey; <sup>h</sup>Memorial Sisli Hospital, Istanbul, Turkey; <sup>i</sup>Ghent University Hospital, Ghent, Belgium; <sup>j</sup>University of Tübingen, Tübingen, Germany; <sup>k</sup>Da Vinci Zentrum, Hanover, Germany; <sup>l</sup>O.L.V. Clinic, Aalst, Belgium

### Article info

#### Article history:

Accepted October 17, 2016

#### Associate Editor:

James Catto

#### Keywords:

Robot-assisted radical cystectomy  
Early recurrence patterns  
Oncologic outcomes  
Totally intracorporeal robot-assisted radical cystectomy

### Abstract

Recurrence following radical cystectomy often occurs early, with >80% of recurrences occurring within the first 2 yr. Debate remains as to whether robot-assisted radical cystectomy (RARC) negatively impacts early recurrence patterns because of inadequate resection or pneumoperitoneum. We report early recurrence patterns among 717 patients who underwent RARC with intracorporeal urinary diversion at nine different institutions with a minimum follow-up of 12 mo. Clinical, pathologic, radiologic, and survival data at the latest follow-up were collected. Recurrence-free survival (RFS) estimates were generated using the Kaplan-Meier method, and Cox regression models were built to assess variables associated with recurrence. RFS at 3, 12, and 24 mo was 95.9%, 80.2%, and 74.6% respectively. Distant recurrences most frequently occurred in the bones, lungs, and liver, and pelvic lymph nodes were the commonest site of local recurrence. We identified five patients (0.7%) with peritoneal carcinomatosis and two patients (0.3%) with metastasis at the port site (wound site). We conclude that unusual recurrence patterns were not identified in this multi-institutional series and that recurrence patterns appear similar to those in open radical cystectomy series.

**Patient summary:** In this multi-institutional study, bladder cancer recurrences following robotic surgery are described. Early recurrence rates and locations appear to be similar to those for open radical cystectomy series.

© 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.

\* Corresponding author. Department of Urology, Karolinska University Hospital, 171 76 Stockholm, Sweden. Tel. +46 8 51772854; Fax: +46 8 51773599.  
E-mail address: [peter.wiklund@karolinska.se](mailto:peter.wiklund@karolinska.se) (P.N. Wiklund).

<http://dx.doi.org/10.1016/j.eururo.2016.10.030>

0302-2838/© 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Please cite this article in press as: Collins JW, et al. Early Recurrence Patterns Following Totally Intracorporeal Robot-assisted Radical Cystectomy: Results from the EAU Robotic Urology Section (ERUS) Scientific Working Group. Eur Urol (2016), <http://dx.doi.org/10.1016/j.eururo.2016.10.030>

Radical cystectomy with extended pelvic lymph node dissection (PLND) provides the best chance of long-term survival for clinically localised muscle-invasive bladder cancer and high-grade recurrent noninvasive disease [1]. However, curative surgery remains challenging, with recurrence rates of 30–40% reported within 5 yr of surgery [2]. Recurrences often occur early; more than 80% occur within the first 2 yr after surgery, with average presentation occurring 10–15 mo after radical cystectomy [3].

Debate remains as to whether minimally invasive surgery negatively impacts survival outcomes due to inadequate resection, suboptimal lymph node dissection, or alteration of recurrence patterns due to tumour seeding related to pneumoperitoneum or insufflation [4]. A recent single-centre study compared open radical cystectomy (ORC) with robot-assisted radical cystectomy (RARC) and reported a similar incidence of overall transitional cell carcinoma (TCC) recurrences, with a higher frequency of peritoneal carcinomatosis and extraperitoneal lymph node recurrences among patients undergoing RARC [4].

It is recognised in ORC series that early recurrence is an indicator of poor prognosis that correlates closely with 5-yr recurrence-free survival (RFS) and overall survival [5]. The current evidence for long-term outcomes following RARC shows acceptable oncologic outcomes comparable to open series [2]. A multicentre study analysing data for 702 RARC patients with a minimum of 5-yr follow-up (median 67 mo) reported 5-yr RFS of 67%.

In the European Association of Urology Robotic Urology Section (ERUS) Scientific Working Group database, 717 patients at nine different institutions were identified who underwent totally intracorporeal RARC between December 2003 and March 2015. The follow-up protocol comprised history, physical examination, urine cytology, and laboratory measurements according to EAU guidelines. Diagnostic imaging was routinely performed at 4–6 mo for the first year, and at least annually thereafter, or more frequently when clinically indicated. The median follow-up was 31 mo (interquartile range [IQR] 20–46).

Patient demographics and oncologic outcomes are summarised in Table 1. Thirty-four patients (4.8%) had a positive surgical margin (PSM), of whom 31 (4.4%) had pT3/T4 disease. Three patients (0.4%) with organ-confined disease had a PSM. The median yield for extended PLND was 18 (IQR 13–25). Kaplan-Meier estimates were created for local and distant recurrence sites (Table 2). RFS at 3, 12, and 24 mo was 95.9%, 80.2%, and 74.6% respectively (Supplementary Fig. 1). Univariable and multivariable Cox regression was used to estimate hazard ratios for predictors of RFS (Supplementary material).

We observed early recurrences at any site in 4.1% of patients at 3 mo, 19.8% at 12 mo, and 25.4% at 24 mo, similar to rates seen in ORC series [5–7]. Distant recurrences were most frequent in the bones, lungs, and liver, while local recurrences were most common in pelvic lymph nodes. This is consistent with recurrence patterns seen in ORC and in autopsy series [6,7]. Regarding unusual recurrence patterns [4], five patients (0.7%) had peritoneal carcinomatosis and two patients (0.3%) had metastasis at the port

**Table 1 – Patient demographics and oncologic outcomes**

| Variable                                 | Result     |
|--|------------|
| Patients (n)                             | 717        |
| Male/female (n)                          | 78/22      |
| Median age, yr (IQR)                     | 68 (62–74) |
| ASA grade (n)                            |            |
| 1  | 17         |
| 2  | 51         |
| 3  | 31         |
| 4  | 1          |
| Median BMI, kg/m <sup>2</sup> (IQR)      | 26 (23–28) |
| Median follow-up, mo (IQR)               | 31 (20–46) |
| Histology, n (%)                         |            |
| Transitional cell carcinoma              | 680 (95.2) |
| Squamous cell carcinoma                  | 20 (2.8)   |
| Adenocarcinoma                           | 9 (1.2)    |
| Neuroendocrine                           | 2 (0.3)    |
| Small cell carcinoma                     | 3 (0.4)    |
| Missing data                             | 3          |
| Preoperative staging, n (%)              |            |
| Carcinoma in situ                        | 34 (4.8)   |
| Ta                                       | 25 (3.5)   |
| T1                                       | 154 (21.6) |
| T2                                       | 370 (52.0) |
| T3                                       | 76 (10.7)  |
| T4                                       | 19 (2.7)   |
| Non-transitional cell carcinoma          | 34 (4.8)   |
| Missing data                             | 5          |
| Received neoadjuvant chemotherapy, n (%) | 176 (25.2) |
| Missing data                             | 19         |
| Pathological stage (%)                   |            |
| pT0                                      | 136 (19.1) |
| pTis                                     | 76 (10.7)  |
| pTa                                      | 34 (4.8)   |
| pT1                                      | 72 (10.1)  |
| pT2                                      | 162 (22.7) |
| pT3                                      | 163 (22.9) |
| pT4                                      | 69 (9.7)   |
| Missing data                             | 5          |
| Soft tissue margin positive, n (%)       | 34 (4.8)   |
| Missing data                             | 2          |
| PLND template, n (%)                     |            |
| No PLND                                  | 35 (5.1)   |
| Standard                                 | 144 (20.8) |
| Extended PLND                            | 518 (74.3) |
| Missing                                  | 20         |
| Pathologic nodal stage, n (%)            |            |
| Nx                                       | 35 (4.9)   |
| N0                                       | 548 (77.1) |
| N1                                       | 58 (8.2)   |
| N2                                       | 70 (9.8)   |
| Missing                                  | 6          |

PLND = pelvic lymph node dissection.

site (wound site), which are both of low incidence and consistent with published ORC series [7]. In a recent review, RFS rates at 2 yr after surgery ranged from 67% to 81% in RARC series [8], and studies highlighting unusual recurrence patterns as a possible indicator of a detrimental effect have not shown a higher incidence of recurrences compared to ORC performed in the same institution [4].

It has been found at autopsy that peritoneal carcinomatosis incidence is as high as 19% among bladder cancer patients, but importantly it is most frequently associated with extensive metastases at multiple sites [6]. Review of the patients in our series with peritoneal carcinomatosis and port-site metastasis revealed that all had high-grade

Download English Version:

<https://daneshyari.com/en/article/5692425>

Download Persian Version:

<https://daneshyari.com/article/5692425>

[Daneshyari.com](https://daneshyari.com)